BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Allanore Y. Limited cutaneous systemic sclerosis: the unfairly neglected subset. Journal of Scleroderma and Related Disorders 2016;1:241-6. [DOI: 10.5301/jsrd.5000216] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Benfaremo D, Svegliati S, Paolini C, Agarbati S, Moroncini G. Systemic Sclerosis: From Pathophysiology to Novel Therapeutic Approaches. Biomedicines 2022;10:163. [DOI: 10.3390/biomedicines10010163] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
2 Lescoat A, Murphy SL, Chen YT, Vann N, Galdo FD, Cella D, Buch MH, Khanna D. Symptom experience of limited cutaneous systemic sclerosis from the Patients' perspective: A qualitative study✰,✰✰,★,★★. Semin Arthritis Rheum 2021:S0049-0172(21)00199-2. [PMID: 34785028 DOI: 10.1016/j.semarthrit.2021.11.003] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Benvenuti F, Zanatta E, Avouac J, Müller-ladner U, Cozzi F, Hoffmann-vold A, Gabrielli A, Distler O, Matucci-cerinic M, Allanore Y, Doria A. The power of the EUSTAR cohort: key findings to date and implications for management of systemic sclerosis patients. Expert Review of Clinical Immunology 2020;16:1065-74. [DOI: 10.1080/1744666x.2021.1836962] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Del Galdo F, Hartley C, Allanore Y. Randomised controlled trials in systemic sclerosis: patient selection and endpoints for next generation trials. The Lancet Rheumatology 2020;2:e173-84. [DOI: 10.1016/s2665-9913(20)30007-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
5 Hamaguchi Y, Takehara K. Anti-nuclear autoantibodies in systemic sclerosis : News and perspectives. Journal of Scleroderma and Related Disorders 2018;3:201-13. [DOI: 10.1177/2397198318783930] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
6 Smirani R, Poursac N, Naveau A, Schaeverbeke T, Devillard R, Truchetet M. Orofacial consequences of systemic sclerosis: A systematic review. Journal of Scleroderma and Related Disorders 2018;3:81-90. [DOI: 10.1177/2397198317746966] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
7 Johnson SR. Progress in the clinical classification of systemic sclerosis. Current Opinion in Rheumatology 2017;29:568-73. [DOI: 10.1097/bor.0000000000000443] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
8 Proudman SM, Huq M, Stevens W, Wilson ME, Sahhar J, Baron M, Hudson M, Pope J, Allanore Y, Distler O, Kowal-bielecka O, Matucci-cerinic M, Low AH, Teng GG, Law WG, Santosa A, Nikpour M; Australian Scleroderma Interest Group (ASIG), Canadian Scleroderma Research Group (CSRG), EULAR Scleroderma Trials and Research group (EUSTAR), Singapore Scleroderma Workgroup (SCORE). What have multicentre registries across the world taught us about the disease features of systemic sclerosis? Journal of Scleroderma and Related Disorders 2017;2:169-82. [DOI: 10.5301/jsrd.5000256] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
9 Bergmann C, Distler JH. Epigenetic factors as drivers of fibrosis in systemic sclerosis. Epigenomics 2017;9:463-77. [DOI: 10.2217/epi-2016-0150] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 4.4] [Reference Citation Analysis]